Eli Lilly re-invests GLP-1 cash into pipeline
The constructive case argued for Eli Lilly is that aggressive M&A using GLP-1 cash flows strengthens long-term pipeline optionality outside core weight-loss drugs.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.